What's News?

Learn more about the latest happenings at PharmaDerm. Choose from the articles below.

PharmaDerm Launches CUTIVATE® Lotion

Atlanta, Georgia – October 17, 2005 - PharmaDerm today announced the official launch of CUTIVATE (fluticasone propionate) Lotion, 0.05%, the only mid-potency steroid lotion approved for patients one year of age and older.

This newest entry into the market offers dermatologists a patent-protected mid-potency lotion for their patients’ skincare needs. The new CUTIVATE Lotion treats atopic dermatitis with an excellent safety profile that includes a low potential to suppress HPA-axis function, even when used under exaggerated conditions.¹ Also, CUTIVATE Lotion offers patients an emollient-rich formulation that relieves symptoms with just once-a-day dosing.

"We are very excited to launch the new CUTIVATE Lotion and to provide dermatologists with a unique mid-potency lotion for their patients’ needs," said Malcolm McCoy, vice president of sales and marketing at PharmaDerm. "CUTIVATE Lotion is the only steroid lotion of its kind approved for patients one year of age and older, providing dermatologists with an effective atopic dermatitis treatment for adult and pediatric patients alike."

The launch of CUTIVATE Lotion comes on the heels of PharmaDerm’s recent acquisition of the prescription dermatology line of GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline Corporation (NYSE: GSK). As part of the acquisition, PharmaDerm will manufacture and market the former GSK products, including ACLOVATE® (alclometasone dipropionate), CUTIVATE® (fluticasone propionate), EMGEL® (erythromycin), OXISTAT® (oxiconazole nitrate), and TEMOVATE® (clobetasol propionate).

Available by prescription, CUTIVATE Lotion comes in a 60 mL bottle.

About PharmaDerm

PharmaDerm, headquartered in Atlanta, GA and a division of ALTANA Inc., is a specialty pharmaceutical manufacturer of topical dermatological prescription products. The company is dedicated to becoming a true innovator in the field of dermatology: to finding new therapies for skin diseases, to giving dermatologists and patients greater access to existing therapies, and to providing a network of resources and expertise to the field of dermatology. For more information on PharmaDerm, please visit the company online at www.pharmaderm.com.

Not for ophthalmic, oral or intravaginal use, or for use by patients with a hypersensitivity to any of its components. In clinical studies, drug-related side effects following the use of CUTIVATE Lotion consisted primarily of localized burning or itching, and were usually mild and self-limiting. No skin atrophy, changes in pigmentation, or evidence of HPA-axis suppression were observed following the use of CUTIVATE Lotion in these studies. Adrenal suppression has been observed in studies with other fluticasone propionate topical formulations.

Back to Top

¹Friedlander SF, Herbert A, Allen DB. Further evidence of safety of topical fluticasone propionate (FP): Under exaggerated conditions of use, a new emulsion preparation has no effect on HPA-axis function. Poster presented at: Annual Meeting of the American Dermatology; February 23, 2005; New Orleans, LA.
See product packaging inserts for full Prescribing Information. ©2005 PharmaDerm, Norcross, GA. All rights reserved.

ALTANA Inc. Acquires US Dermatology Business From GlaxoSmithKline Consumer Healthcare

Melville, New York - September 30, 2005 - ALTANA Inc, a wholly owned subsidiary of ALTANA Pharma AG, announced today that it has acquired the prescription dermatology business from GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline Corporation (NYSE: GSK). PharmaDerm, a division of ALTANA Inc, will manufacture and market the former GSK products to include:

• Aclovate® (alclometasone dipropionate), a synthetic corticosteroid.
• Cutivate® (fluticasone propionate), an anti-inflammatory.
• Emgel® (erythromycin), an antibiotic.
• Oxistat® (oxiconazole nitrate), an anti-fungal.
• Temovate® (clobetasol propionate), an anti-inflammatory.

"This transaction represents a key acquisition on the branded side of our business and supports the ALTANA Inc specialty business. It is a significant step in the formation of PharmaDerm and toward achieving our goal of becoming the leading pharmaceutical company specializing in dermatology," said Paul B. McGarty, Chief Executive Officer of ALTANA Inc.

The acquisition marks an expansion of PharmaDerm’s current portfolio, which includes flagship products ApexiCon E Cream® (diflorasone diacetate cream USP, 0.05% [emollient]) for steroid responsive dermatoses such as eczema, psoriasis and contact dermatitis and ClindaMax® Lotion (clindamycin phosphate topical suspension USP, 1%), for the treatment of acne. "This acquisition represents our ongoing commitment to expand our business by providing dermatologists with additional solutions for their patients’ needs," said Malcolm McCoy, Vice President of Sales and Marketing at PharmaDerm. "The addition of new product lines allows us to significantly enhance our existing sales and marketing capability and to broaden our offering to the dermatology marketplace."

In March 2005, GlaxoSmithKline received FDA approval for Cutivate® Lotion. Yet to mark its official launch, Cutivate Lotion will add a valuable exclusive asset to PharmaDerm’s product portfolio. "We will move forward with plans to launch Cutivate Lotion this fall and are especially excited about offering dermatologists an effective, mid-potency steroid for their adult and pediatric patients," McCoy added. Financial terms of the deal were not disclosed.

About PharmaDerm

PharmaDerm, headquartered in Atlanta, GA is a division of ALTANA Inc, the leading US specialty pharmaceutical manufacturer of topical dermatological prescription products. The company is committed to providing dermatologists with exceptional industry support and offering flexible, easy-to-use and cosmetically elegant products for dermatologists and their patients. The company’s current line of dermatological pharmaceuticals includes ApexiCon E Cream® (diflorasone diacetate cream USP, 0.05% [emollient]), ApexiCon® Ointment (diflorasone diacetate ointment USP, 0.05%), ClindaMax® Lotion (clindamycin phosphate topical suspension USP, 1%), ClindaMax® Gel (clindamycin phosphate gel), and LoKara^TM (desonide lotion, 0.05%). For more information on PharmaDerm, please visit the company online at www.pharmaderm.com.

About ALTANA Inc

ALTANA Inc is one of two U.S. subsidiaries of ALTANA Pharma AG, an international pharmaceutical company headquartered in Germany. ALTANA Inc is the managing group for four divisions including: Fougera and PharmaDerm, which produce topical dermatologic ointments and creams; Pharmaderm Animal Health, a manufacturer of topical preparations for animal care, and Savage Laboratories, marketers of the antidotes CroFab^TM and DigiFab® for hospital emergency medicine departments. For more information, call 1-800-432-6673 or log onto www.ALTANAinc.com.

Back to Top

Statements about the organization's future expectations, other than historical facts, are "forward looking statements", based on appraisals by the PharmaDerm management and information currently available to PharmaDerm. Factors, which PharmaDerm cannot predict with certainty, may cause actual results to vary substantially from those specifically or implicitly expected in these statements.

®ApexiCon and ClindaMax are registered trademarks, and ^TMLoKara is a trademark of PharmaDerm, a division of ALTANA Inc.

©2005 PharmaDerm, Norcross, GA. All rights reserved.

See product packaging inserts for full prescribing information.

PharmaDerm Launches ApexiCon^TM E Cream

Atlanta, Georgia - January 30, 2004 -- PharmaDerm, a division of ALTANA Inc, is excited to announce the introduction of their latest product, ApexiCon^TME Cream (diflorasone diacetate emollient cream USP, 0.05%) and Ointment (diflorasone diacetate ointment USP, 0.05%), for the topical treatment of corticosteroid responsive dermatoses.

The introduction of a high and ultra high potency topical steroid complements the recently launched LoKara Lotion (desonide lotion, 0.05%) low potency steroid product and further demonstrates PharmaDerm’s commitment to the support of dermatology and dermatologists’ practices.

ApexiCon is the third product launched to market since January of 2003 by PharmaDerm. "We are all very proud of what we have been able to accomplish in such a short period of time,” said Malcolm McCoy, Vice President of Sales and Marketing for PharmaDerm Human. “We have grown from a regional sales force and no products to market, and in 13 months time, we are now a sales force with a national presence and have launched our third product to market, this is truly extraordinary.”

ApexiCon^TM E Cream and Ointment, shipped to wholesalers in early January, is being introduced to Dermatologists during the last week of January. “ApexiCon E Cream and Ointment further demonstrate our commitment to the products dermatologists consider to be cornerstones of their armamentarium of prescriptions, which are currently under sourced, but in great demand,” continued Mr. McCoy.

ApexiCon will be available across the continental United States. ApexiCon is a diflorasone diacetate based topical, corticosteroid with high to ultra high potency. ApexiCon E Cream and Ointment are available in 30g and 60g tubes, which, as with all PharmaDerm’s products, are promoted exclusively to Dermatologists.

For full ApexiCon^TM Ointment product information and to view an electronic version of the Product Insert, please Click Here.

For full ApexiCon^TM E Cream product information and to view an electronic version of the Product Insert, please Click Here.

Back to Top

PharmaDerm, headquartered in Atlanta GA and a division of ALTANA Inc., is a new dynamic dermatological company dedicated to dermatologists and their patients. For more information on PharmaDerm and our complete line of quality products, please call PharmaDerm Customer Service at (866) DERM-001 (337-6001) or visit the company online at www.pharmaderm.com.

Statements about the organization's future expectations, other than historical facts, are "forward looking statements", based on appraisals by the PharmaDerm management and information currently available to PharmaDerm. Factors, which PharmaDerm cannot predict with certainty, may cause actual results to vary substantially from those specifically or implicitly expected in these statements